Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1809 results
February 2023
-
Media Release
Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®
In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis at Week… -
In Colombia, a researcher works against a devastating disease
Alexandra Cossio Duque, a clinical and community research coordinator from Colombia, has travelled the world to study how to overcome social and geographic barriers to healthcare access. Today, she is working in her home country to strengthen the capacity of health systems to treat leishmaniasis, a neglected tropical disease that is endemic to rural areas of Colombia.
-
Going upstream to improve heart health in Philadelphia
Cardiovascular disease is the leading cause of death in the US, claiming one in four lives. Social factors such as living conditions, education and diet play a key role in determining a person’s heart health, which means cardiovascular disease typically hits vulnerable communities the hardest. Our three-year Closing the Gap initiative with the Jefferson Collaborative for Health Equity (established by Jefferson Health and Thomas Jefferson University) focuses on addressing the upstream social determinants of heart health in five vulnerable neighborhoods in Philadelphia with high rates of stroke and adverse outcomes related to heart disease.
-
A cancer patient gets a new lease on life
After being diagnosed with advanced prostate cancer, Van Lacour received a Novartis radioligand therapy as part of a managed access program in 2021. Today, he is living a fulfilling life in his hometown of Natchez, Louisiana, US.
-
Empowering the next generation of healthcare leaders
As part of the Beacon of Hope initiative, the Novartis Institutes for BioMedical Research (NIBR) in Cambridge, Massachusetts, US, offers 10-week paid summer fellowships for students at Historically Black Medical Schools to gain experience in drug discovery, data analytics and clinical research practices - with the goal of training up to 250 scientific leaders over 10 years.
-
Key Release
Novartis poursuit sa croissance avec une nouvelle expansion de sa marge core et franchit des étapes importantes dans l’innovation
Annonce événementielle au sens de l’art. 53 RCExercice entier Chiffre d’affaires net en hausse de +4% (tcc1, -2% USD) et résultat opérationnel core croissant de +8% (tcc, 0% USD) Innovative… -
Key Release
Novartis setzt Wachstumskurs mit weiterer Steigerung der Kerngewinnmarge fort und erreicht wichtige Innovations-meilensteine
Ad-hoc-Mitteilung gemäss Art. 53 KR Geschäftsjahr Der Nettoumsatz stieg um +4% (kWk1, –2% USD), wobei sich das operative Kernergebnis um +8% (kWk, 0% USD) verbesserte Innovative… -
Key Release
Novartis continues to grow with further core margin expansion and achieves important innovation milestones
Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +4% (cc1, -2% USD) with core operating income growing +8% (cc, 0% USD) IM sales grew +4% (cc, -2% USD) and core operating income…
January 2023
-
Media Release
Sandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilar
Sandoz is seeking approval of high concentration formulation (HCF) adalimumab for use in all indications of reference medicine Upon approval, HCF formulation will offer patients enhanced yet familiar… -
Statement
Novartis provides update on Phase III STAND trial assessing crizanlizumab
-
Media Release
Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio
Sandoz plans to acquire worldwide product rights for Mycamine® (micafungin sodium) from AstellasAcquiring leading global echinocandin, one of three major antifungal classes, will significantly… -
Pulse Update
Novartis shares strategy insights and highlights key pipeline catalysts at JP Morgan Healthcare Conference 2023
Pagination
- ‹ Previous page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- …
- 151
- › Next page